Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Diagnostic Accuracy of Large Language Models for Peri-Implant Marginal Bone Loss on Panoramic Radiographs

NCT07907900 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-10-27
Last updated
2026-10-30

Condition(s) studied

Peri-implantitisAlveolar Bone LossDental Implant

Investigational drug(s) / intervention(s)

Multimodal large language model evaluation (ChatGPT, Gemini, Claude, DeepSeek, Grok)

Multimodal large language model evaluation (ChatGPT, Gemini, Claude, DeepSeek, Grok): Each anonymized ROI image is uploaded to five multimodal large language models using an identical standardized zero-shot prompt; the model assigns a Froum and Rosen score (0-3). Outputs are compared with the clinician reference standard.

Study summary

Dental implants are a routine treatment for missing teeth, but the number of implants affected by peri-implantitis, a progressive inflammatory disease of the tissues around implants, is increasing. The main radiographic sign of peri-implantitis is marginal bone loss around the implant. Early detection and correct grading of this bone loss in proportion to implant length are important for treatment planning and prognosis.

Panoramic radiographs are widely used for general screening in dental practice, but judging bone loss on them is subjective, time-consuming and depends on the clinician's experience. Multimodal large language models (vision-language models) are increasingly able to interpret images, yet their ability to evaluate peri-implant bone loss on panoramic radiographs has not been tested.

This single-center, retrospective, observational diagnostic accuracy study will evaluate how accurately five publicly available large language models (ChatGPT, Gemini, Claude, DeepSeek and Grok) detect and grade peri-implant marginal bone loss on anonymized, cropped panoramic radiographs of functionally loaded dental implants, compared with a reference standard established by three blinded clinicians (two periodontologists and one oral and maxillofacial radiologist). Bone loss will be graded with the Froum and Rosen (2012) classification: Score 0 (no visible bone loss), Score 1 (\<25% of implant length), Score 2 (25-50%) and Score 3 (\>50%).

Approximately 784 implant sites (392 with and 392 without marginal bone loss) from existing panoramic radiographs in the hospital archive will be included. No new radiographs will be taken, no patient will be contacted and no treatment will be given; informed consent has been waived by the ethics committee. All images will be fully anonymized before evaluation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Panoramic radiographs of adult patients (18 years or older) obtained during routine clinical care at Ankara University Faculty of Dentistry and stored in the hospital PACS archive * At least one dental implant visible on the radiograph (with or without marginal bone loss) * Bone-level implant in function, i.e., prosthetic loading completed * Diagnostic image quality (contrast and sharpness) sufficient to clearly evaluate implant borders, threads, implant platform and the adjacent crestal bone Exclusion Criteria: * Records of patients younger than 18 years * High distortion due to patient movement, positioning error or device-related causes, or radiographic artifacts over the implant body or marginal bone that prevent evaluation * Implants not yet prosthetically loaded (submerged or healing-abutment stage) * Dense radiopaque bone graft material around the implant masking the natural marginal bone level * Cystic lesions or tumoral formations around the implant that could be confused with, or completely distort, ordinary peri-implant marginal bone loss

Primary outcome measure(s)

  • Sensitivity and specificity of each large language model for detecting peri-implant marginal bone loss — Single time point, at completion of model evaluation (approximately 8 weeks after study start); retrospective images, no follow-up
    For each of the five models (ChatGPT, Gemini, Claude, DeepSeek, Grok): sensitivity and specificity for the presence of marginal bone loss (Froum and Rosen Score 1-3 vs Score 0) on anonymized panoramic ROI images, calculated against the consensus reference standard of three blinded clinicians, with 95% confidence intervals.

Trial sites (1)

FacilityCityRegionStatus
Ankara University Faculty of Dentistry Ankara Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07907900 on ClinicalTrials.gov ↗ ← All trials in Turkey